Results 61 to 70 of about 1,763 (188)

Oligoprogression in non-small cell lung cancer: a narrative review

open access: yesJournal of Thoracic Disease, 2022
Non-small cell lung cancer (NSCLC) accounts for 80% of lung cancers and is the most common non-cutaneous cancer world-wide. In NSCLC, oligometastatic and oligoprogressive disease (OPD) have been recognized as separate entities within the realm of metastatic disease and are emerging concepts in the context of targeted systemic therapies.
Nguyen, Katarina T.   +4 more
openaire   +2 more sources

Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection

open access: yes, 2022
Oligoprogression is defined as limited metastatic clone resistant to on-going systemic treatment that grows in a background of stable or responding systemic disease.
Marzo, Marco Antonio   +19 more
core   +1 more source

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma

open access: yesBiomedicines, 2023
The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for BRAF-mutant melanoma. In oligoprogressive melanoma patients with BRAF mutations, target therapy can be combined with loco-regional radiotherapy (RT).
Rossi E.   +12 more
openaire   +3 more sources

Prognostic Factors and Optimal Response Interval for Stereotactic Body Radiotherapy in Patients With Lung Oligometastases or Oligoprogression From Colorectal Cancer

open access: yesFrontiers in Oncology, 2019
Purpose: To analyze the prognostic factors and optimal response interval for stereotactic body radiotherapy (SBRT) in patients with lung oligometastases (OM) or oligoprogression (OP) from colorectal cancer (CRC).Method: Patients with lung OM or OP from ...
Shuai Li   +11 more
doaj   +1 more source

Time to Next Treatment Following Sub-Ablative Progression Directed Radiation Therapy for Oligoprogressive Non-Small-Cell Lung Cancer

open access: yesCurrent Oncology
We aimed to evaluate whether progression-directed radiation therapy (PDRT) can prolong the initiation of a subsequent systemic therapy regimen in a cohort of patients with oligoprogressive NSCLC.
Riccardo Ray Colciago   +10 more
doaj   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown   +7 more
wiley   +1 more source

Locoregional control to overcome oligoprogression during immunotherapy in HER2-mutant non-small cell lung cancer

open access: yes
HER2-mutant NSCLC, HER2-mutation, immunotherapy, oligoprogression, stereotactic body radiotherapy, locoregional control, abscopal effect.
D.G. Ishchanov   +4 more
core   +1 more source

The role of radiotherapy in the treatment of oligometastatic non-small cell lung cancer

open access: yesReports of Practical Oncology and Radiotherapy
In the recent years, the clinical stage where the cancer has spread beyond the primary site, but has not yet metastasised extensively, and which is known as oligometastatic disease (OMD), has become an object of interest to radiation oncologists.
Radovan Vojtišek
doaj   +1 more source

Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment

open access: yesJournal of Evidence-Based Medicine, Volume 19, Issue 2, June 2026.
ABSTRACT The rapid advancement of radiotherapy techniques and systemic anticancer agents has created unprecedented opportunities to improve outcomes for breast cancer patients, while also introducing new challenges related to optimal integration and safety.
Jie Lan   +18 more
wiley   +1 more source

Fruquintinib Plus TAS‐102 With or Without SBRT as Third‐ Or Later‐Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase II Trial

open access: yesCancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Both fruquintinib and TAS‐102 monotherapies are guideline‐recommended for third‐line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS‐102, with or without stereotactic body radiation therapy (SBRT), as a third‐ or later‐line therapy for mCRC.
Yi Wang   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy